BHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bausch Health Companies Inc (BHC) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance is weak, with significant losses in net income and EPS. Analysts have lowered price targets, and there are no recent positive catalysts or strong trading signals to support a buy recommendation. While the stock has some technical indicators showing potential short-term upward momentum, the long-term outlook remains uncertain due to pipeline challenges and loss of exclusivity concerns.
The MACD histogram is positive and expanding, indicating potential upward momentum. RSI is in the neutral zone at 76.097, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level of 5.783, with support at 5.271. Overall, technical indicators suggest limited short-term upside.
No significant positive catalysts identified. The MACD and gross margin improvement are minor positives.
Analysts have lowered price targets, citing concerns about loss of exclusivity for key drugs and failed Phase 3 trials. Financial performance has deteriorated significantly, with a sharp decline in net income and EPS. No recent news or influential trades to support a positive outlook.
In Q4 2025, revenue increased by 9.26% YoY, but net income dropped by -220.43% YoY to -$112 million. EPS also fell by -220% YoY to -0.3. Gross margin improved slightly to 63.02%, up 2.52% YoY.
Barclays lowered the price target from $8 to $7, maintaining an Equal Weight rating. Truist highlighted challenges with the failed Phase 3 trials and concerns about the loss of exclusivity for Xifaxan, maintaining a Hold rating with a price target of $8.
